CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 186 enrolled
Drug / intervention
10-valent pneumococcal conjugate vaccine, PCV10biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04912297
NCT04912297N/ACompleted
CompareCT.gov

Persistence of Humoral Immunity to Serotype 19A Streptococcus Pneumoniae in Children Vaccinated With the 10-valent Pneumococcal Conjugate Vaccine in Finland

Finnish Institute for Health and Welfare·observational·Posted Jun 3, 2021·Updated Aug 11, 2021

In Brief

An observational study evaluating 10-valent pneumococcal conjugate vaccine, PCV10 for Pneumococcal Infections. Completed, enrolled 186 participants across 1 site.

Detailed Summary

The aim of the study are to assess the persistence of immunity against vaccine serotypes (VSTs) and vaccine-related serotypes in PCV10 vaccinated children in Finland.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPneumococcal Infections
CountriesFinland
CollaboratorsTurku University Hospital, GlaxoSmithKline

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 3, 2021
Enrollment StartNov 12, 2009
Primary CompletionMay 7, 2013
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 5.1 years ago

Interventions

10-valent pneumococcal conjugate vaccine, PCV10biological

10-valent pneumococcal conjugate vaccine, PCV10